Sangamo BioSciences (SGMO) drops 36.8% premarket after announcing it didn't meet the clinical...

|About: Sangamo BioSciences, Inc. (SGMO)|By:, SA News Editor

Sangamo BioSciences (SGMO) drops 36.8% premarket after announcing it didn't meet the clinical endpoints it hoped to achieve in a Phase 2b trial of its SB-509 drug for treating diabetic neuropathy. As a result, Sangamo plans to discontinue development of SB-509.